Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
Status:
Completed
Trial end date:
2017-12-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety, tolerability,
pharmacokinetics/pharmacodynamics and efficacy of CFZ533 as an add-on therapy to standard of
care in patients with moderate to severe myasthenia gravis (MG).